



Moss Genomics Announces Listing on the OTC Markets

Vancouver, BC, April 11, 2025 – Moss Genomics Inc. (CSE: MOSS) (OTCQB: MSSGF) (FSE: F73) (the “Company” or “Moss”) is pleased to announce that its common shares are now listed for trading on the **OTC Markets** under the ticker **MSSGF**. This milestone significantly expands Moss’s accessibility for U.S.-based investors and enhances overall share liquidity by enabling trading through U.S. broker-dealers.

The listing on the OTC Markets is part of Moss’s broader strategy to align with global capital markets while increasing visibility and participation from the international investment community.

Moss Genomics is a biotechnology company developing next-generation **genomics products** that empower individuals to gain greater control over their personal health data. The Company is currently testing a beta version of **Perennial**, a consumer-focused platform that allows users to upload their blood test results and receive personalized health insights based on key biomarkers.

The Company’s shares will continue to trade on the **Canadian Securities Exchange (CSE)** under the symbol **MOSS** and the **Frankfurt Stock Exchange (FSE)** under the symbol **F73**.

For more information on Moss Genomics, please visit: <https://mossgenomics.com>
To view the OTC Markets profile: <https://www.otcmarkets.com/stock/MSSGF/overview>

About Moss Genomics Inc.

Moss Genomics is a biotechnology company focused on genomics and microbiome research to develop advanced genetic insights and solutions. The company leverages blockchain technology to enhance security and user control over genomic information. Along with its genomics-focused products, Moss Genomics deploys an Ethereum accumulation strategy as part of its treasury management, currently holding 160 ETH on its balance sheet.

For further information concerning Moss and its business, please view the Company's website at <https://mossgenomics.com/> and its SEDAR+ profile at www.sedarplus.ca or contact us at:

CONTACT INFORMATION

Moss Genomics Inc.

Jack Liu, Chief Executive Officer and Director

Email: invest@mossgenomics.com

Telephone: 604-710-0124



The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Information

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information

can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements, referred to herein as “forward-looking statements”, are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things: the Company's intention to leverage the blockchain to advance its genomics business; the Company's belief that blockchain technology will enhance data security, privacy, and user control over genomic information; the Company's belief that its product offerings will make genetic insights more accessible and secure; the Company's belief that Ethereum will represent a viable alternative to traditional fiat currencies as part of the Company's treasury management system; and that the Company's listing on the OTC Markets will increase visibility and participation from the international investment community.

These forward-looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the risk that the Company will be unable to utilize the blockchain in an effective manner for the advancement of its genomics business; the risk that the blockchain technology will not notably enhance data security, privacy or user control over genetic information; the risk that the Company's product offerings are unable to make genetic insights more accessible or secure; the risk that Ethereum will not represent a viable alternative to traditional fiat currencies for use in a treasury management system; and the risk that the OTC Markets listing will not create a notable increase in visibility and participation from the international investment community.

In making the forward looking statements in this news release, the Company has applied several material assumptions, including without limitation, that: blockchain technologies can be effectively implemented into the Company's genomics business model and can be implemented in a cost-effective and timely manner; the privacy and security offered by decentralized blockchain technology will be superior to the privacy and security over user data which may be available through other means; that the Company's use of blockchain as part of its business model will improve access to genetic insights; and that the use of Ethereum in the Company's treasury management system will reflect a viable alternative to traditional fiat currencies, including the risk that commercial partners of the Company are or become unwilling to accept Ethereum as consideration for products and services.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.

Cryptocurrency Market Risks

The Company would like to remind investors that markets for cryptocurrencies have experienced much larger fluctuations than other markets, and there can be no assurances that significant swings in price will slow in the future. In the event that the price of cryptocurrencies decline, the value of an investment in the Company could also decline. As well, momentum pricing is typically associated with assets whose valuation, as determined by the investing public, accounts for anticipated future appreciation in value. Momentum pricing of cryptocurrency may result in speculation regarding future appreciation in the value of cryptocurrency. As a result, changing

investor confidence could adversely affect an investment in the Company. Additionally, there is no assurance that cryptocurrency will become a leading means of digital payment. Any slowing or stopping of the development in the acceptance of cryptocurrency may adversely affect an investment in the Company. Furthermore, there is a risk that cryptocurrency trading platforms, or the Company's digital wallets may be compromised. Access to the Company's crypto-assets, maintained in a hosted online wallet, could also be restricted as a result of cyber crime. Any of these events may adversely affect the operations of the Company and, consequently, its business and profitability.